SCHEDULE: RA Capital Discloses 5.5% Stake in Benitec Biopharma
Ownership Disclosure
RA Capital Management and its affiliates have disclosed a 5.5% beneficial ownership stake in Benitec Biopharma Inc., holding 1,850,000 shares of common stock.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The Reporting Persons beneficially own an aggregate of 1,850,000 shares of Benitec Biopharma Inc. common stock.
- This ownership represents 5.5% of the Issuer's outstanding common stock.
- The percentage is based on 33,862,226 shares outstanding as of November 14, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q.
- The filing indicates a passive investment, with the Reporting Persons certifying that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The disclosure of a significant institutional stake by RA Capital Management is generally viewed positively as it indicates investor confidence, although it is a standard regulatory filing without explicit positive or negative news from the company itself.
Positives
- A significant institutional investor, RA Capital Management, has taken a 5.5% stake in Benitec Biopharma Inc., potentially signaling confidence in the company's prospects.
Future Outlook
The filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding future performance or strategy.
Industry Context
The investment by RA Capital Management, a prominent healthcare-focused investment firm, in Benitec Biopharma Inc. suggests continued institutional interest in the biotechnology and biopharmaceutical sectors, particularly in companies with potential in novel therapeutic areas.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor like RA Capital Management taking a 5.5% stake could be perceived positively, potentially increasing investor confidence and market liquidity.
Next Steps
- The filing does not mention any specific future actions or milestones for Benitec Biopharma Inc. or the Reporting Persons beyond regulatory compliance.
Key Dates
| Date | Description |
|---|---|
| 11/07/2025 | Date of event which requires filing of this statement. |
| 11/14/2025 | Date as of which 33,862,226 shares of common stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q. |
| 12/03/2025 | Date of signing of the Schedule 13G and Joint Filing Agreement by the Reporting Persons. |
Keywords
Benitec Biopharma, RA Capital Management, Schedule 13G, Institutional Ownership, Biopharma Investment, Equity Stake, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.